Sweden: Laroprovstat, the first oral small-molecule PCSK9 inhibitor under clinical development, demonstrated substantial LDL cholesterol–lowering effects in a phase 1 study involving treatment-naive ...

“As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination with different doses of a statin, will make it easier for physicians to ...

Significantly lower AMD risk compared with other agents in cohort study ...

CKD patients face higher CVD risk, with dyslipidemia differing from the general population, necessitating tailored lipid management strategies. Statin-based therapies, especially simvastatin plus ...

LDL cholesterol still drives treatment decisions in assessing heart disease risk, but a new study suggests apolipoprotein B (apoB), which measures artery-clogging particles, could do a better job. In ...

In a breakthrough for cardiovascular medicine, researchers have harnessed artificial intelligence to discover unexpected lipid-lowering effects in existing FDA-approved drugs. The study, published in ...

High cholesterol is a common health concern in the United States, affecting nearly 10% of adults. Elevated cholesterol levels are linked to a greater risk of cardiovascular diseases, like heart ...

They’ll support your overall heart health, too.

A staggering 28 million adults in the United States have high cholesterol, meaning they have too many lipids (fats) in their blood. That number, from the Centers for Disease Control and Prevention ...

Millions more adults should consider starting cholesterol-lowering medications earlier to reduce their risk of heart attack and stroke, according to new medical guidance. In an updated guideline ...